Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained prior to participation in the study.~* Patients with type 1 or type 2 diabetes mellitus (DM) and Hemoglobin A1c (HbA1c) ≤ 12% at screening.~* Study eye: Visual impairment due to DME with:~  * Best-corrected visual acuity (BCVA) score between 73 and 23 letters, inclusive, using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts at an initial testing distance of 4 meters~ * DME involving the center of the macula, with Central Subfield Thickness (CSFT) ≥ 320 µm on Spectral Domain Optical Coherence Tomography (SD-OCT)~Exclusion Criteria:~* High-risk proliferative diabetic retinopathy (PDR) in the study eye~* Concomitant conditions or ocular disorders in the study eye which confound interpretation of study results, compromise visual acuity or require medical or surgical intervention~* Any active intraocular or periocular infection or active intraocular inflammation in the either eye~* Uncontrolled glaucoma in the study eye~* Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA \<20/200~* Use of anti-VEGF therapies, intraocular surgery or laser photocoagulation (macular or panretinal) in the study eye during the 3-month period prior to baseline~* Use of intraocular or periocular corticosteroids in the study eye during the 6-month period prior to baseline, and use of fluocinolone acetonide intravitreal (IVT) implant (Iluvien) at any time prior to baseline~* Prior investigational drugs in either eye, vitreoretinal surgery in the study eye at any time prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6mg q4w (Type: EXPERIMENTAL): Brolucizumab 6 mg/0.05 mL every 4 weeks.
- Aflibercept 2mg q4w (Type: ACTIVE_COMPARATOR): Aflibercept 2mg/0.05 mL every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).